MedTrace Logo

Imaging Study of Glioblastomas Treated With Avastin

NCT01549392 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2014-09-15

Study results available
· View outcomes & findings →

Summary

This study aims to assess the effect of Avastin on brain vascularity and blood-brain permeability using dynamic contrast ct scans (DECT) and MRI imaging. Previous publications have documented the method by which DECT can determine alterations in vascular volume and tissue permeability within tumors and normal brain tissue. Functional maps of cerebral blood flow cerebral blood volume and permeability-surface area can be generated from the DECT studies to assess tumor perfusion. MRI spectroscopy analyzes brain chemistry to detect tumour versus edema versus normal brain. Thirty patients will receive MRI spectroscopy and DECT imaging at the time of presumed recurrence and 3 months later. 15 patients who do not receive Avastin and 15 patients who do receive Avastin as standard treatment for recurrence will be studied with DECT and MRI spectroscopy at baseline and then again in 3 months.

Conditions

  • Malignant Gliomas

Interventions

DEVICE

DECT

DECT at tumor progression and 3 months later

DEVICE

MR spectroscopy

MR spectroscopy at tumor progression and 3 months later

Sponsors & Collaborators

  • University of Western Ontario, Canada

    collaborator OTHER

  • London Regional Cancer Program, Canada

    collaborator OTHER

  • London Health Sciences Centre

    lead OTHER

Principal Investigators

  • Barbara J Fisher, MD · London Regional Cancer Program

Study Design

Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-02-29
Primary Completion
2014-03-31
Completion
2014-03-31

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01549392 on ClinicalTrials.gov